Public Release: 

New measurement of HDL cholesterol function provides information about cardiovascular risk

UT Southwestern Medical Center

IMAGE?

IMAGE: This is Dr. Anand Rohatgi, Assistant Professor of Internal Medicine at UT Southwestern. view more

Credit: UT Southwestern Medical Center

DALLAS - November 18, 2014 - Groundbreaking research from UT Southwestern Medical Center shows that cholesterol efflux capacity (cholesterol efflux), which measures HDL cholesterol function, appears to be a superior indicator of cardiovascular risk and a better target for therapeutic treatments than standard measurements of HDL. Current measurement methods reflect only the circulating levels of HDL and not the functional properties of this lipoprotein.

The latest findings appear online today in The New England Journal of Medicine.

HDL's key function is the removal of cholesterol from plaque in blood vessels and delivery to the liver for excretion. Until recently, this functional property could not be measured. The new study, led by Dr. Anand Rohatgi, Assistant Professor of Internal Medicine at UT Southwestern, measured cholesterol efflux using this new method of measurement in more than 3,000 participants from a multi-ethnic, population-based cohort known as the Dallas Heart Study.

The study found that this functional measurement of cholesterol efflux provided significantly different information than did standard measurements of HDL cholesterol. The findings uncovered a significant protective relationship between cholesterol efflux and cardiovascular risk. The better a person's cholesterol efflux, the less likely he or she was to suffer a heart attack, stroke, or death from heart disease. The association was much stronger for cholesterol efflux than for the traditional measurement of HDL cholesterol level.

HDL cholesterol has long been considered good cholesterol because numerous population studies have shown a consistent, strong, inverse relationship between HDL cholesterol levels and risk of heart disease. "Unfortunately, that observation has not translated into effective therapies that target HDL cholesterol," said Dr. Rohatgi. "Niacin raises HDL cholesterol 20-25 percent and newer drugs called CETP inhibitors raise HDL cholesterol even more, but none have been shown to reduce cardiac events."

"So now we're looking under the hood, so to speak, and we're realizing that the whole story of what HDL does is not being told by HDL cholesterol levels alone," said Dr. Rohatgi. "HDL is very dynamic. It has many functions that are not fully captured by the measurement of static cholesterol levels. The hypothesis has changed from an HDL-cholesterol hypothesis to an HDL-function hypothesis to better capture cardiovascular risk and provide a better target for therapy to reduce that risk."

Atherosclerosis, which is a hardening and narrowing of the arteries, is caused by the buildup of fatty plaques made up of cholesterol and cells on artery walls. Atherosclerosis is the leading cause of heart attacks, and understanding how HDL acts to remove cholesterol from these plaques could offer a target for reducing heart disease risk.

"We drew on the strengths of the Dallas Heart Study to thoroughly investigate the relationship between HDL function and cardiovascular disease," said Dr. Rohatgi. "What we found was a strong, graded, protective relationship between cholesterol efflux and incidence of cardiovascular events among people who were free from heart disease at baseline testing."

This is the first report of a measure of HDL function in a population-based study and supports future studies investigating HDL cholesterol efflux and cardiovascular disease.

###

Other UT Southwestern researchers who contributed to the study include Dr. Amit Khera, Associate Professor of Internal Medicine and holder of the Dallas Heart Ball Chair in Hypertension and Heart Disease; Dr. Jarett Berry, Associate Professor of Clinical Science and Internal Medicine; Edward Givens, research technician; Colby Ayers, faculty associate in Clinical Science; Dr. Ian Neeland, cardiology fellow; Dr. Ivan Yuhanna, research associate; Dr. James de Lemos, Professor of Internal Medicine and holder of the Sweetheart Ball-Kern Wildenthal, M.D., Ph.D. Distinguished Chair in Cardiology; and senior author Dr. Philip Shaul, Professor of Pediatrics and holder of the Associates First Capital Corporation Distinguished Chair in Pediatrics.

The research was supported by grants from the National Institutes of Health, the American Heart Association, and the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The Dallas Heart Study was supported by the Donald W. Reynolds Foundation and by the National Center for Advancing Translational Sciences of the NIH.

About UT Southwestern Medical Center

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution's faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. Numbering approximately 2,800, the faculty is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to about 92,000 hospitalized patients and oversee approximately 2.1 million outpatient visits a year.

This news release is available on our home page at http://www.utsouthwestern.edu/home/news/index.html

To automatically receive news releases from UT Southwestern via email, subscribe at http://www.utsouthwestern.edu/receivenews

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.